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Introduction 
 
The World Health Organization recently highlighted the continuing scandal of unacceptably 
high levels of maternal and child deaths in developing countries in their World Health Report 
for 2005 (1). This shows that 30,000 children under 5 years of age still die each day. In recent 
years malaria, TB and HIV /AIDS have received global attention in high profile scientific 
publications and major international disease control initiatives (for example the Roll Back 
Malaria, Stop TB, DOTS and “3 by 5” programmes) (2-4). This international response has 
been reinforced by significant new funding mechanisms and sources such as the Global Fund 
to fight AIDS, TB and Malaria and the major financial contributions from the Bill and 
Melinda Gates Foundation to the development of new vaccines against these scourges. 
However, these conditions account for about 11% of all child deaths globally, while 
pneumonia and diarrhoea are jointly responsible for nearly half of all child deaths (5). This is 
about the same as the number of deaths from smoking, double the total number of deaths from 
HIV/AIDS and is 25 times the number of deaths from war globally. Despite this huge 
mortality, we recently found a steep decreasing trend in research publications on the global 
extent of these problems reflecting reduced research interest and investment over the past 2 
decades (6) (Figure 1). This was in line with the report of the Global Forum for Health 
Research for 2004, where it was shown that diarrhoea and pneumonia research receive 
markedly lower investments that those allocated to other diseases that contribute significantly 
to global child mortality (7). 
 
Why should there be depleted scientific interest in field studies trying to better understand 
these two conditions – childhood pneumonia and diarrhoea - at a time when the WHO has 
again shown that these remain two of the most important causes of global burden of disease in 
children? Why do these two diseases continue to be responsible for almost half of all child 
deaths globally, when interventions exist to prevent most of these deaths, interventions that 
were developed and proven highly cost-effective more than two decades ago (8,9)? It is clear 
that these interventions are not being delivered to the children who most need them (10). 
Programmes aiming to deliver these interventions have been inadequately funded, of poor 
quality, not sustained and not expanded from initial pilots often in least deprived regions (11). 
Our failure in delivering the interventions is caused by our lack of understanding of how to do 
it efficiently and creatively in low resource settings, and it is a challenge for research to 
generate the required knowledge.  
 We propose that a major reason for these failures has been the lack of recognition that low 
coverage is a challenge for health research, to identify effective and efficient context-specific 
delivery mechanisms in health services of countries with limited resources. The development 
and proof of effective interventions has been seen in the past as the legitimate endpoint of 
research. Implementation research that needs to follow (including health policy and systems 
research and delivery research) is methodologically challenging and may require long-term 
studies. It has not been ranked as highly by the scientific community or by most funding 
agencies as new work in basic science or intervention development. This has tragic 
consequences. It has been shown that up to two thirds of under-five child deaths globally 
could be prevented today if available and cost-effective interventions were delivered to those 
in need (10). This would achieve UN’s Millennium Development Goal 4, and is affordable 
within current global financial resources (10,12). 
 
We believe that this experience with these two forgotten killers is a good predictor of what 
can be expected to occur in the future if the current research investment model is to persist 
(Figure 2). Effective new interventions such as vaccines against AIDS, TB or malaria may be 
developed in the coming decade, but the same challenge will then be faced: how to make 
those vaccines cheaper and more cost-effective, and how to deliver them to those most in 
need? The potential public health impact of these new interventions will not be realised 
without research on implementation. 
 
The dominant model of research priority setting is resulting in gross under-achievement of 
potential disease burden reduction and is actually generating further health inequity. Current 
major global funding initiatives favour the areas of research interest of the scientists involved 
in basic research, thus investing into options which have received the greatest level of 
advocacy and media coverage and whose future potential outputs appear most attractive to 
these communities and the agencies which support them. This is further encouraged by the 
greater potential for publications in high-impact journals, which is a major indicator of 
research quality, and also funding in the current research policy model (Figure 2). When these 
new research avenues lead to the successful development of new interventions, the initial 
beneficiaries usually are those who can afford the results of the research. More complete 
coverage of the population in need often lags decades behind (12-14). It is apparent that 
global research priorities and media pressure fuelled by an interest in highly unusual 
individual cases or emerging but uncertain threats are bound to generate ever increasing 
inequity. We believe that a major underlying problem is lack of clear principles for health 
research investment based on a vision of what the endpoints of such investments should be. 
We need a framework which values investment not only in generating new knowledge, but 
also in research that seeks to define how to implement and make better use of the existing 
knowledge leading to public health impact on burden of disease  
 
A New Model of Priority Setting for Global Health Research Investments 
 
The Commission on Health Research for Development was the most significant initial 
development in setting research priorities globally (15). It reviewed global health needs and 
priorities for health research in 1990 and concluded that “...less than 10% of global health 
research funds is devoted to 90% of the world’s health problems” (13). A number of 
subsequent initiatives addressed this problem by attempting to set priorities in global health 
research, including the recommendations from the Ad Hoc Committee on Health Research 
Relating to Future Intervention Options in 1996 (16), The Council on Health Research and 
Development in 2000 (17), “The Grand Challenges” in Global Health supported by The Gates 
Foundation that emerged from World Economic Forum in 2003 (18), and the Combined 
Approach Matrix tool by the Global Forum for Health Research in 2004 (19). Another 
initiative is now underway by The Lancet itself to identify health research priorities to address 
UN Millenium Development Goals 4 and 5 through a two-stage Delphi study. All these 
approaches have in common that they are very useful for gathering information relevant to 
setting research priorities, but the process itself then eventually depends on a limited number 
of technical experts who collect this information and then recommend priorities, which makes 
it highly susceptible to their own individual opinions and personal interests and biases. 
 
The Child Health and Nutrition Research Initiative (CHNRI), an initiative of the Global 
Forum for Health Research, is now leading a project which seeks to overcome these concerns. 
The major conceptual advance in this initiative is the recognition that there should be a 
broader definition of health research option as an activity that is not only limited to producing 
new knowledge, but also has a vision of implementation of this knowledge which, in the end, 
should help to reduce disease burden present today. From this it follows that it is important 
not to consider the endpoint of research as "generating new and interesting knowledge or 
insight", because this necessarily favours more fundamental research. Rather, the process of 
research priority setting should have a clear theoretical framework based on multiple 
endpoints coupled to a systematic process of scoring and ranking competing research options. 
In Figure 2, we illustrate the alternative model proposed by CHNRI, which addresses several 
components of a research option that can be used as criteria for setting research priorities: (i) 
likelihood that research option would be answerable in ethical way; (ii) likelihood that 
resulting intervention would be effective in reducing disease burden; (iii) deliverability, 
affordability and sustainability of resulting intervention; (iv) maximum potential of 
intervention to reduce disease burden; and (v) effect of disease burden reduction on equity in 
population. We believe it is also important to acknowledge that there are three different 
instruments of health research (IHRs, Figure 3). For example, health policy and systems 
research will reduce disease burden by improving efficiency of health systems in delivering 
the interventions, implementation research will aim to improve existing non-affordable 
interventions to make them feasible and affordable in low-income settings, while other types 
of research will seek new and non-existing interventions. The former two types of research 
are not as innovative and attractive as the latter one, and their results are unlikely to be 
publishable in journals of high impact, but they nevertheless carry a significant potential to 
reduce the existing disease burden.  
 
We are concerned that the current research priority decision making is not driven by an 
explicit framework and value system and thus is too open to research interest bias of 
individuals who influence funding priorities in large donor agencies without an unbiased 
vision focused on reducing disease burden and improving global health inequities. The six 
main advantages of the CHNRI methodology presented in Figure 3 over the alternative 
approaches are: (i) it is systematic, and technical experts involved the process to set research 
priorities are asked to list and score competing research options in a highly structured way; 
this limits the influence of their own personal biases on the outcome, which is frequently a 
problem in Delphi studies; (ii) the methodology is entirely transparent; all rationales for 
decision making and input from each person involved from the initial to the final stages are 
recorded, displayed and can be viewed and challenged at any later point in time; (iii) the 
experts submit their input into the process independently from each other, and the results are 
based on their collective opinion in a true sense, thus avoiding the possibility of some 
individuals among them directing the process; (iv) the final result is a simple quantitative 
outcome (“research priority score”), which measures the “value” of each research option 
when all the criteria and stakeholders’ views are taken into account; this “value” can then be 
combined with the proposed cost of research in order to perform program budgeting and 
marginal analysis and derive an optimal mix of research options to be funded from a fixed 
budget; (v) the methodology is well suited to simultaneously evaluate and score different 
types of research (e.g. health policy and systems research, implementation research and 
research on new interventions) using the same set of criteria; (vi) unlike all previous 
approaches, this methodology incorporates an efficient means of considering the voice of 
stakeholders and wider public, who are given the power to place thresholds and weights upon 
intermediate scores (which are based on collective opinion of technical experts) and in this 
way considerably shape the final outcome (see Figure 3). 
 
This methodology has been recently implemented with success at both international and 
national levels. At the global level, CHNRI and WHO Child and Adolescent Health 
Department are now working together using this methodology and global childhood mortality 
burden estimates (provided recently by WHO Child Health Epidemiology Reference Group) 
to define research priorities for each of the 8 main causes of child deaths (5). This 
methodology has also been applied recently at the national level. A total of 63 health research 
options addressing 7 main causes of child deaths in South Africa were listed (9 options per 
cause of death) and scored by local technical experts, with their results adjusted by local 
stakeholders (Tomlinson M, Chopra M and Rudan I, personal communication). In Table 1, we 
present final scores and rankings of those research options that addressed pneumonia and 
diarrhoea. Eight research options addressing those two diseases were placed among the top 13 
research priorities, thus correctly recognizing the magnitude of their effect on mortality 
burden in South Africa. Furthermore, the priorities identified were dominated by health policy 
and systems research options to increase the coverage of the simplest and most cost-effective 
interventions, such as hand-washing, breastfeeding and increased usage of antibiotic treatment 
of pneumonia (Table 1). 
 
Although all initiatives aiming to set priorities and invest in child health research in 
developing countries are welcome, it is important to understand that without an explicit 
consideration of the issues listed above, the health gains that can be achieved will be limited. 
There are signs that these issues are beginning to gain attention. Some examples include the 
Research Assessment Exercise in the UK, a major driver of research priorities in public 
sector, debating how to respond to criticisms that the system undervalues health systems 
research; the European Commission, announcing that there will be a new funding stream for 
Health Policy and Systems Research in the forthcoming 7 year research programme (FP7) 
and, in the field of pneumonia, the grants by the Global Alliance for Vaccines and 
Immunisation for public-private partnerships and related research to accelerate the 
achievement of high levels of population coverage of immunisation with the new Hemophilus 
influenzae type b and pneumococcal protein conjugate vaccines. These initiatives are 
welcome but there is a need for a new framework for global health research priority setting, 
especially in child health research. We believe that only in this way will proper attention be 
given to delivery of proven interventions to reduce the high childhood mortality due to 
pneumonia and diarrhoea. 
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 Legends to figures and a table 
 
Figure 1: Number of papers with policy-relevant information on epidemiology of specific 
childhood illnesses in developing countries identified by WHO Child Health Epidemiology 
Reference Group shows depleting interest in diseases that continue to kill most children 
(Rudan et al., 2005) (MAL - malaria; NEO - neonatal causes; ARI - acute respiratory 
infections; DIA - diarrhoea; MB - morbidity; MT – mortality) 
 
Figure 2: A diagram showing the criteria used in setting priorities in global health research 
investments: the current approaches (left), and the approach proposed by CHNRI (right). 
 
Figure 3: A figure showing all the steps of proposed CHNRI methodology at a glance: 
gathering a working group of technical experts who are expected to define the context (space, 
time, population and disease burden addressed); list research options systematically based on 
potential risk factors, interventions and 3 instruments of health research (IHR); score the 
competing research options independently and in a highly structured way, according to 5 
criteria relevant to priority setting; address the input from stakeholders; and perform program 
budgeting and marginal analysis, to define the optimal mix of assessed overall value of 
research for invested funding. 
 
Table 3: Selected results from research priority setting exercise conducted in April 2006 to 
address South African child health research priorities (covering 7 major causes of child deaths 
in the country: HIV/AIDS, malnutrition, neonatal problems, diarrhoea, pneumonia, congenital 
and genetic disorders, accidents and injuries). For each cause of death, 9 research options 
were proposed for scoring by local experts (3 for each of the three instrument of health 
research, IHR). The final research priority scores (RPS) were based on scoring by technical 
experts and adjusting the scores according to the system of values of 30 members of larger 
reference group representing the stakeholders in the country. The rankings of 18 research 
options that addressed childhood pneumonia and diarrhoea are presented. 
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RPS 
(x100) 
Rank Disease IHR Research option 
87.8 2/63 Diarrhoea 1 Health policy and systems research to increase hand-washing with soap 
87.7 3/63 Pneumonia 1 HPSR to achieve increased usage of antibiotic treatment for pneumonia 
84.2 5/63 Diarrhoea 1 HPSR and education/behaviour modification research to increase exclusive breastfeeding in first 6 months 
83.5 6/63 Pneumonia 1 HPSR to improve existing ways of training health workers to deliver pneumonia standard case management 
83.3 7/63 Diarrhoea 1 HPSR to increase awareness of indications for treatment and access to ORS sachets at all times and sites 
80.3 10/63 Diarrhoea 2 Research to reduce costs /improve deliverability and sustainability of piped safe water systems 
77.6 12/63 Diarrhoea 2 Research to develop ways of sewage treatment systems affordable to developing countries 
75.6 13/63 Pneumonia 1 HPSR to increase zinc supplementation coverage 
68.4 24/63 Diarrhoea 3 Low cost no electrical/no fuel consuming refrigerators to storage food at home level 
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49.7 59/63 Pneumonia 2 Research to reduce the costs of oxygen therapy and make it more available to the general public 
 
 
 
